Generic placeholder image

Mini-Reviews in Medicinal Chemistry

Author(s): Xing Lv, Mingzhu Zhang and Wen Xu*

DOI: 10.2174/1389557523666230313144742

DownloadDownload PDF Flyer Cite As
The Value of Emerging Prostate Cancer-associated lncRNA PCGEM1 in Various Tumors

Page: [2090 - 2096] Pages: 7

  • * (Excluding Mailing and Handling)

Abstract

Background: LncRNA not only plays an auxiliary role as an intermediate carrier of genetic information, but also mediates various regulatory functions. The complex and precise regulatory function of lncRNA in development and gene expression has greatly explained the complexity of the genome, and also opened a new avenue for people to understand the complexity of life from the dimension of gene expression. Long non-coding RNA (lncRNA) prostate cancer gene expression marker 1 (PCGEM1) is a characterized oncogenic lncRNA in different cancers. This review is dedicated to summarizing the various molecular mechanisms of PCGEM1 and demonstrates that the biological functions exerted by PCGEM1 are good starting points for therapy.

Methods: The molecular mechanism of PCGEM1 acting on tumors has been summarized by reviewing the literature available on PubMed.

Results: The expression of lncRNA PCGEM1 is abnormally increased in all kinds of tumors, including cervical cancer, prostate cancer, renal carcinoma, gastric cancer, lung cancer, ovarian carcinoma, cough variant asthma, and castration tolerant prostate cancer. Besides, PCGEM1 mediates multiple processes involved in carcinogenesis, including proliferation, invasion, anti-apoptosis, and migration.

Conclusion: The potential of PCGEM1 as a therapeutic target for cancer is revealed.

Graphical Abstract

[1]
St Laurent, G.; Wahlestedt, C.; Kapranov, P. The Landscape of long noncoding RNA classification. Trends Genet., 2015, 31(5), 239-251.
[http://dx.doi.org/10.1016/j.tig.2015.03.007] [PMID: 25869999]
[2]
Han, Z.; He, J.; Zou, M.; Chen, W.; Lv, Y.; Li, Y. Small interfering RNA target for long noncoding RNA PCGEM1 increases the sensitivity of LNCAP cells to baicalein. Anat. Rec., 2020, 303(8), 2077-2085.
[http://dx.doi.org/10.1002/ar.24454] [PMID: 32445497]
[3]
Parolia, A.; Crea, F.; Xue, H.; Wang, Y.; Mo, F.; Ramnarine, V.R.; Liu, H.H.; Lin, D.; Saidy, N.R.N.; Clermont, P.L.; Cheng, H.; Collins, C.; Wang, Y.; Helgason, C.D. The long non-coding RNA PCGEM1 is regulated by androgen receptor activity in vivo. Mol. Cancer, 2015, 14(1), 46.
[http://dx.doi.org/10.1186/s12943-015-0314-4] [PMID: 25744782]
[4]
Buskwofie, A.; David-West, G.; Clare, C.A. A review of cervical cancer: Incidence and disparities. J. Natl. Med. Assoc., 2020, 112(2), 229-232.
[http://dx.doi.org/10.1016/j.jnma.2020.03.002] [PMID: 32278478]
[5]
Okunade, K.S. Human papillomavirus and cervical cancer. J. Obstet. Gynaecol., 2020, 40(5), 602-608.
[http://dx.doi.org/10.1080/01443615.2019.1634030] [PMID: 31500479]
[6]
Liu, Y.; Wang, Y.; Shen, X.; Chen, C.; Ni, H.; Sheng, N.; Hua, M.; Wu, Y. Down-regulation of lncRNA PCGEM1 inhibits cervical carcinoma by modulating the miR-642a-5p/LGMN axis. Exp. Mol. Pathol., 2020, 117, 104561.
[http://dx.doi.org/10.1016/j.yexmp.2020.104561] [PMID: 33121976]
[7]
Xue, Y.; Wang, M.; Kang, M.; Wang, Q.; Wu, B.; Chu, H.; Zhong, D.; Qin, C.; Yin, C.; Zhang, Z.; Wu, D. Association between lncrna PCGEM1 polymorphisms and prostate cancer risk. Prostate Cancer Prostatic Dis., 2013, 16(2), 139-144.
[8]
Fu, X.; Ravindranath, L.; Tran, N.; Petrovics, G.; Srivastava, S. Regulation of apoptosis by a prostate-specific and prostate cancer-associated noncoding gene, PCGEM1. DNA Cell Biol., 2006, 25(3), 135-141.
[http://dx.doi.org/10.1089/dna.2006.25.135] [PMID: 16569192]
[9]
Hirsch, G.E. Parisi, M.M.; Martins, L.A.M.; Andrade, C.M.B.; Barbé-Tuana, F.M.; Guma, F.T.C.R. γ-oryzanol reduces caveolin-1 and PCGEM1 expression, markers of aggressiveness in prostate cancer cell lines. Prostate, 2015, 75(8), 783-797.
[http://dx.doi.org/10.1002/pros.22960] [PMID: 25619388]
[10]
Petrovics, G.; Zhang, W.; Makarem, M.; Street, J.P.; Connelly, R.; Sun, L.; Sesterhenn, I.A.; Srikantan, V.; Moul, J.W.; Srivastava, S. Elevated expression of PCGEM1, a prostate-specific gene with cell growth-promoting function, is associated with high-risk prostate cancer patients. Oncogene, 2004, 23(2), 605-611.
[http://dx.doi.org/10.1038/sj.onc.1207069] [PMID: 14724589]
[11]
Liu, H.; He, X.; Li, T.; Qu, Y.; Xu, L.; Hou, Y.; Fu, Y.; Wang, H. PCGEM1 promotes proliferation, migration and invasion in prostate cancer by sponging miR-506 to upregulate TRIAP1. BMC Urol., 2022, 22(1), 14.
[http://dx.doi.org/10.1186/s12894-022-00969-x] [PMID: 35109849]
[12]
Fu, Q.; Wang, F.; Yang, J.; Sun, W.; Hu, Z.; Xu, L.; Chu, H.; Wang, X.; Zhang, W. Long non-coding RNA-PCGEM1 contributes to prostate cancer progression by sponging microRNA miR-129-5p to enhance chromatin licensing and DNA replication factor 1 expression. Bioengineered, 2022, 13(4), 9411-9424.
[http://dx.doi.org/10.1080/21655979.2022.2059936] [PMID: 35412947]
[13]
Zhang, S.; Li, Z.; Zhang, L.; Xu, Z. MEF2 activated long non coding RNA PCGEM1 promotes cell proliferation in hormone refractory prostate cancer through downregulation of miR 148a. Mol. Med. Rep., 2018, 18(1), 202-208.
[http://dx.doi.org/10.3892/mmr.2018.8977] [PMID: 29749452]
[14]
He, J.H.; Zhang, J.; Han, Z.P.; Wang, L.; Lv, Y.B.; Li, Y.G. Reciprocal regulation of PCGEM1 and miR-145promote proliferation of LNCaP prostate cancer cells. J. Exp. Clin. Cancer Res., 2014, 33(1), 72.
[http://dx.doi.org/10.1186/s13046-014-0072-y] [PMID: 25200485]
[15]
Parker, C.C.; James, N.D.; Brawley, C.D.; Clarke, N.W.; Hoyle, A.P.; Ali, A.; Ritchie, A.W.S.; Attard, G.; Chowdhury, S.; Cross, W.; Dearnaley, D.P.; Gillessen, S.; Gilson, C.; Jones, R.J.; Langley, R.E.; Malik, Z.I.; Mason, M.D.; Matheson, D.; Millman, R.; Russell, J.M.; Thalmann, G.N.; Amos, C.L.; Alonzi, R.; Bahl, A.; Birtle, A.; Din, O.; Douis, H.; Eswar, C.; Gale, J.; Gannon, M.R.; Jonnada, S.; Khaksar, S.; Lester, J.F.; O’Sullivan, J.M.; Parikh, O.A.; Pedley, I.D.; Pudney, D.M.; Sheehan, D.J.; Srihari, N.N.; Tran, A.T.H.; Parmar, M.K.B.; Sydes, M.R. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): A randomised controlled phase 3 trial. Lancet, 2018, 392(10162), 2353-2366.
[http://dx.doi.org/10.1016/S0140-6736(18)32486-3] [PMID: 30355464]
[16]
Ho, T.T.; Huang, J.; Zhou, N.; Zhang, Z.; Koirala, P.; Zhou, X.; Wu, F.; Ding, X.; Mo, Y.Y. Regulation of PCGEM1 by p54/nrb in prostate cancer. Sci. Rep., 2016, 6(1), 34529.
[http://dx.doi.org/10.1038/srep34529] [PMID: 27682980]
[17]
Herbst, R.S.; Morgensztern, D.; Boshoff, C. The biology and management of non-small cell lung cancer. Nature, 2018, 553(7689), 446-454.
[http://dx.doi.org/10.1038/nature25183] [PMID: 29364287]
[18]
Weng, L.; Qiu, K.; Gao, W.; Shi, C.; Shu, F. LncRNA PCGEM1 accelerates non-small cell lung cancer progression via sponging miR-433-3p to upregulate WTAP. BMC Pulm. Med., 2020, 20(1), 213.
[http://dx.doi.org/10.1186/s12890-020-01240-5] [PMID: 32787827]
[19]
Huang, J.; Lou, J.; Liu, X.; Xie, Y. LncRNA PCGsEM1 contributes to the proliferation, migration and invasion of non-small cell lung cancer cells via acting as a sponge for miR-152-3p. Curr. Pharm. Des., 2021, 27(46), 4663-4670.
[http://dx.doi.org/10.2174/1381612827666210827104828] [PMID: 34455968]
[20]
Wen, H.; Feng, H.; Ma, Q.; Liang, C. Retracted article: LncRNA PCGEM1 induces proliferation and migration in non-small cell lung cancer cells through modulating the miR-590-3p/SOX11 axis. BMC Pulm. Med., 2021, 21(1), 234.
[http://dx.doi.org/10.1186/s12890-021-01600-9] [PMID: 34261474]
[21]
Menon, U.; Karpinskyj, C.; Gentry-Maharaj, A. Ovarian cancer prevention and screening. Obstet. Gynecol., 2018, 131(5), 909-927.
[22]
Chen, S.; Wang, L.; Sun, K.; Liu, Y.; Guan, X.; Zong, Z.; Zhao, Y. LncRNA PCGEM1 induces ovarian carcinoma tumorigenesis and progression through RhoA pathway. Cell. Physiol. Biochem., 2018, 47(4), 1578-1588.
[http://dx.doi.org/10.1159/000490931] [PMID: 29949791]
[23]
Karimi, P.; Islami, F.; Anandasabapathy, S.; Freedman, N.D.; Kamangar, F. Gastric cancer: Descriptive epidemiology, risk factors, screening, and prevention. Cancer Epidemiol. Biomarkers Prev., 2014, 23(5), 700-713.
[http://dx.doi.org/10.1158/1055-9965.EPI-13-1057] [PMID: 24618998]
[24]
Jiang, H.; Guo, S.; Zhao, Y.; Wang, Y.; Piao, H.; Wu, Y.; Zhang, J. Circulating long non-coding RNA PCGEM1 as a novel biomarker for gastric cancer diagnosis. Pathol. Res. Pract., 2019, 215(10), 152569.
[http://dx.doi.org/10.1016/j.prp.2019.152569] [PMID: 31421977]
[25]
Xia, X.; Wang, S.; Ni, B.; Xing, S.; Cao, H.; Zhang, Z.; Yu, F.; Zhao, E.; Zhao, G. Hypoxic gastric cancer-derived exosomes promote progression and metastasis via MiR-301a-3p/PHD3/HIF-1α positive feedback loop. Oncogene, 2020, 39(39), 6231-6244.
[http://dx.doi.org/10.1038/s41388-020-01425-6] [PMID: 32826951]
[26]
Zhang, J.; Jin, H.Y.; Wu, Y.; Zheng, Z.C.; Guo, S.; Wang, Y.; Yang, D.; Meng, X.Y.; Xu, X.; Zhao, Y. Hypoxia-induced LncRNA PCGEM1 promotes invasion and metastasis of gastric cancer through regulating SNAI1. Clin. Transl. Oncol., 2019, 21(9), 1142-1151.
[http://dx.doi.org/10.1007/s12094-019-02035-9] [PMID: 30690667]
[27]
Piao, H.; Guo, S.; Wang, Y.; Zhang, J. Exosome-transmitted lncRNA PCGEM1 promotes invasive and metastasis in gastric cancer by maintaining the stability of SNAI1. Clin. Transl. Oncol., 2021, 23(2), 246-256.
[http://dx.doi.org/10.1007/s12094-020-02412-9] [PMID: 32519176]
[28]
Zhang, T.; Piao, H.; Guo, S.; Zhao, Y.; Wang, Y.; Zheng, Z.; Zhang, J. LncRNA PCGEM1 enhances metastasis and gastric cancer invasion through targeting of miR-129-5p to regulate P4HA2 expression. Exp. Mol. Pathol., 2020, 116, 104487.
[http://dx.doi.org/10.1016/j.yexmp.2020.104487] [PMID: 32622013]
[29]
Campbell, S.C.; Uzzo, R.G.; Karam, J.A.; Chang, S.S.; Clark, P.E.; Souter, L. Renal mass and localized renal cancer: Evaluation, management, and follow-up: AUA Guideline: Part II. J. Urol., 2021, 206(2), 209-218.
[http://dx.doi.org/10.1097/JU.0000000000001912] [PMID: 34115531]
[30]
Cai, X.; Zhang, X.; Mo, L.; Zhu, J.; Yu, H. LncRNA PCGEM1 promotes renal carcinoma progression by targeting miR-433-3p to regulate FGF2 expression. Cancer Biomark., 2020, 27(4), 493-504.
[http://dx.doi.org/10.3233/CBM-190669] [PMID: 31958075]